Lantheus’ product, PYLARIFY (piflufolastat F18) injection, is the first and only commercially available and FDA-approved PSMA-targeted PET imaging agent for prostate cancer
San Francisco, CA (UroToday.com) — Lantheus Holdings, Inc. (the “Company”), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions, announced that prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with piflufolastat F 18 has been included in recently updated National Comprehensive Cancer Network® (NCCN) Guidelines® for prostate cancer. The NCCN Guidelines® are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors.